[ad_1]
Mkhize was speaking after data from one of the experiments showed that the AstraZeneca vaccine offered only limited protection against mild disease caused by the new strain of coronavirus that was first discovered in South Africa. South.
British pharmaceutical company AstraZeneca said on Saturday that its vaccine, developed by the University of Oxford, appeared to offer only limited protection against mild illness caused by the South African type of Covid-19 disease, based on the first data of a test.
A Financial Times report released earlier today said the study by the University of the Witwatersrand in South Africa and the University of Oxford showed the vaccine’s effect to be significantly small compared to the type South African.
Among the coronavirus mutations that currently worry scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to be spreading faster than others.
A spokesperson for AstraZeneca said in response to the Financial Times report, “In this second small trial of the first phase, early data showed limited efficacy against mild symptoms primarily caused by the B1.351 African variant. South.”
“However, we were not able to properly confirm its effect against severe symptoms and hospitalization because the people who had the test were mostly healthy adults.”
The company said it believes its vaccine can prevent severe symptoms, given that the activity of the neutralizing antibodies is similar to that of other Covid-19 vaccines.
[ad_2]
Source link
